Relationship of nervous tissue transketolase to the neuropathy in chronic uremia.
Patients with chronic uremia develop neurologic defects which are similar to the demyelinating lesions seen in thiamine deficiency. The present study describes inhibitory effects of uremic material on nervous tissue transketolase, a thiamine-dependent enzyme of the pentose phosphate pathway which has been reported to have functional importance in the metabolism of myelinated nervous structures. Transketolase activity (TKA) of normal human brain and spinal cord was measured by the conversion of ribose-5-phosphate (R5P) to sedoheptulose-7-phosphate (S7P). TKA was significantly inhibited by plasma, cerebrospinal fluid and low molecular weight dialysate fractions obtained from patients with uremic neuropathy, but not by samples from normal subjects. The specific effect on transketolase by uremic material was established by showing suppressed formation of S7P from R5P also in the presence of excess cofactor thiamine pyrophosphate and of the other substrate xylulose-5-phosphate. Uremic plasma likewise inhibited a partially purified transketolase preparation from bakers' yeast.31 of 35 chronic uremic patients with inhibition values between 10 and 84% before or during the early phase of intermittent hemodialysis had evidence of neuropathy. Data of clinical grading of the neurologic deficits and values of motor nerve conduction velocity revealed a correlation between the extent of uremic neuropathy and the degree of nervous tissue transketolase inhibition. Hemodialysis markedly reduced the inhibitory effects of the patients' plasma and the data indicate that uremic patients who received effective long-term dialysis treatment show a parallel decline of transketolase inhibition and uremic neuropathy.The findings demonstrate that in patients with chronic renal failure, low molecular weight factors accumulate and inhibit nervous tissue transketolase. This biochemical defect-uncorrectable by thiamine but reversible by dialysis-may interfere with the metabolism of myelin-supporting cells, and/or of the axonal metabolism of medullated structures, and may thus contribute to the degeneration of myelinated nerves seen with uremic neuropathy.
D000293:Adolescent; D000328:Adult; D001921:Brain / Q000201:enzymology*; D003711:Demyelinating Diseases / Q000097:blood / Q000201:enzymology*; D005260:Female; D006539:Heptoses / Q000096:biosynthesis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010292:Paresthesia / Q000201:enzymology*; D010428:Pentosephosphates / Q000378:metabolism; D006435:Renal Dialysis; D012266:Ribose / Q000378:metabolism; D013116:Spinal Cord / Q000201:enzymology*; D013832:Thiamine Deficiency / Q000150:complications; D013835:Thiamine Pyrophosphate / Q000378:metabolism; D014166:Transferases / Q000037:antagonists & inhibitors / Q000097:blood / Q000378:metabolism*; D014511:Uremia / Q000097:blood / Q000378:metabolism*
D006539:Heptoses; D010428:Pentosephosphates; D012266:Ribose; D014166:Transferases; D013835:Thiamine Pyrophosphate